In the latest session, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.54 down -0.33% from its previous closing price of $0.55. On the day, 1348410 shares were traded.
Ratios:
For a deeper understanding of Sangamo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.63 while its Price-to-Book (P/B) ratio in mrq is 1.17.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $1.80, while it has fallen to a 52-week low of $0.29.
Shares Statistics:
A total of 203.67M shares are outstanding, with a floating share count of 183.15M. Insiders hold about 10.07% of the company’s shares, while institutions hold 49.19% stake in the company.
Earnings Estimates
There are Silicon Motion Technology Corpo different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $14.65, with high estimates of $4.83 and low estimates of $0.54.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Basic Materials.
